v3.26.3
Interests in Other Entities (Tables)
 12 Months Ended
Jun. 30, 2026
Interests in Other Entities [Abstract]  
Schedule of Group’s Subsidiaries

The group’s subsidiaries at 30 June 2026 are set out below. Unless otherwise stated, they have share capital consisting solely of ordinary shares that are held directly by the group, and the proportion of ownership interests held equals the voting rights held by the group. The country of incorporation or registration is also their principal place of business.

 

    Place of
business/		   Ownership interest held by
the group		     Ownership interest held by
non-controlling interests		  
Name of entity   country of
incorporation		   2026
%		     2025
%		     2026
%		     2025
%		  
Radiopharm Theranostics (USA) Inc   United States     100       100       -       -  
Radiopharm Ventures LLC   United States     87.5       75       12.5       25  
Pharma15 Corporation   United States     100       100       -       -  
Schedule of Summarized Balance Sheet

Comparatives are not disclosed below as Radiopharm Ventures, LLC was established in the 2023 financial year.

 

    Radiopharm Ventures, LLC  
Summarized statement of financial position   30 June
2026
$		     30 June
2025
$		  
Current assets     -       -  
Current liabilities     -       -  
Current net assets     -       -  
                 
Non-current assets     1,107,185       1,229,761  
Non-current net assets     1,107,185       1,229,761  
      -          
Net assets     261,074       1,152,892  
      -          
Accumulated non-controlling interests     (2,363,526 )     (1,920,100 )
Schedule of Summarized Statement of Comprehensive Loss
    Radiopharm Ventures, LLC  
Summarized statement of comprehensive loss   30 June
2026
$		     30 June
2025
$		  
Loss for the year     (11,227,807 )     (6,110,449 )
Total comprehensive loss     (11,227,807 )     (6,110,449 )
      -          
Loss allocated to non-controlling interests     (1,801,344 )     (1,639.368 )